B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Executive Director – Small Molecule CMC Lead

Full-Time
$274.8k - $354.8k/yr+ Annual bonus plan + Discretionary equity awards + Employee Stock Purchase Plan
Expert
Master's, PharmD, PhD
Hopewell, VA, USA
In Person
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A Ph.D. or equivalent degree in Pharmaceutical Sciences, Chemistry, Chemical Engineering, Biochemistry, or a related discipline; an advanced degree (MS/PharmD) with extensive pharmaceutical industry experience may be considered.
  • At least 8 years of pharmaceutical or biotechnology industry experience in CMC development.
  • Demonstrated experience leading CMC activities for NCE through clinical development and regulatory approval.
  • Experience supporting successful IND and NDA submissions.
  • Strong understanding of CMC development, GMP manufacturing, and regulatory CMC expectations.
  • Proven ability to lead cross-functional teams without direct authority.
  • Strong strategic thinking and problem-solving capability.
  • Ability to make data-driven decisions under uncertainty.
  • Excellent communication skills with technical, executive, and regulatory stakeholders.
Responsibilities
  • Develop and execute comprehensive CMC strategies aligned with overall development objectives and corporate goals.
  • Lead CMC planning and execution across development stages, including pivotal clinical development, registration submission, commercial manufacturing readiness, and post-approval lifecycle management.
  • Define critical CMC milestones, deliverables, timelines, resource needs, and risk mitigation strategies.
  • Provide strategic oversight of drug substance and drug product development activities, ensuring processes are scientifically sound, robust, scalable, and suitable for GMP manufacturing; partner with CDMOs and manufacturing sites to support successful clinical and commercial supply execution.
  • Ensure appropriate analytical strategies are established to support product development and regulatory requirements, and that analytical packages support regulatory submissions and lifecycle management.
  • Partner with Regulatory Affairs to develop high-quality CMC regulatory strategies and support preparation of regulatory briefing packages, responses to agency questions, and commitments.
  • Establish effective governance mechanisms for CMC decision-making and lead technical assessments and trade-off decisions balancing quality, speed, cost, regulatory expectations, and long-term commercial needs.
  • Identify CMC risks and establish mitigation plans throughout development.
  • Provide strategic oversight of CDMOs and external vendors, ensuring they deliver against agreed scope, timelines, quality standards, and budgets; lead escalation management when needed.
  • Support transition from development to commercial manufacturing, ensuring CMC readiness for PPQ campaigns, regulatory submissions and inspections, launch supply, and post-approval changes.
  • Develop lifecycle strategies to improve product robustness, cost, capacity, and supply reliability.
  • Serve as the primary CMC representative on cross-functional development teams.
  • Lead collaboration among CMC technical functions, commercial manufacturing, QA/QC, regulatory CMC, clinical development, supply chain, and external CDMO partners.
  • Ensure effective communication, alignment, and decision-making across functions.
  • Drive resolution of complex technical and operational challenges.
Desired Qualifications
  • Experience leading multiple pipeline programs simultaneously.
  • Experience managing both internal and outsourced development and manufacturing models.
  • Experience with global regulatory agencies, including FDA, EMA, and NMPA.
  • Experience with commercialization, technology transfer, PPQ, and post-approval lifecycle management.
  • Experience building CMC organizations or implementing CMC governance models.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • Wellness Program
  • Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.